Cervical cancer: Epidemiology, risk factors and screening
- PMID: 33446995
- PMCID: PMC7797226
- DOI: 10.21147/j.issn.1000-9604.2020.06.05
Cervical cancer: Epidemiology, risk factors and screening
Abstract
Cervical cancer is one of the leading causes of cancer death among females worldwide and its behavior epidemiologically likes a venereal disease of low infectiousness. Early age at first intercourse and multiple sexual partners have been shown to exert strong effects on risk. The wide differences in the incidence among different countries also influenced by the introduction of screening. Although the general picture remains one of decreasing incidence and mortality, there are signs of an increasing cervical cancer risk probably due to changes in sexual behavior. Smoking and human papillomavirus (HPV) 16/18 are currently important issues in a concept of multifactorial, stepwise carcinogenesis at the cervix uteri. Therefore, society-based preventive and control measures, screening activities and HPV vaccination are recommended. Cervical cancer screening methods have evolved from cell morphology observation to molecular testing. High-risk HPV genotyping and liquid-based cytology are common methods which have been widely recommended and used worldwide. In future, accurate, cheap, fast and easy-to-use methods would be more popular. Artificial intelligence also shows to be promising in cervical cancer screening by integrating image recognition with big data technology. Meanwhile, China has achieved numerous breakthroughs in cervical cancer prevention and control which could be a great demonstration for other developing and resource-limited areas. In conclusion, although cervical cancer threatens female health, it could be the first cancer that would be eliminated by human beings with comprehensive preventive and control strategy.
Keywords: Cervical cancer; epidemiology; risk factors; screening.
Copyright © 2020 Chinese Journal of Cancer Research. All rights reserved.
Similar articles
-
[Epidemiology of cervix cancer--a review].Arch Geschwulstforsch. 1987;57(5):401-16. Arch Geschwulstforsch. 1987. PMID: 3318755 Review. German.
-
Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.Arch Med Res. 2009 Aug;40(6):503-13. doi: 10.1016/j.arcmed.2009.08.004. Arch Med Res. 2009. PMID: 19853192
-
Epidemiology of cancer of the cervix: global and national perspective.J Indian Med Assoc. 2000 Feb;98(2):49-52. J Indian Med Assoc. 2000. PMID: 11016150
-
Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.Lancet Oncol. 2018 Dec;19(12):1569-1578. doi: 10.1016/S1470-2045(18)30536-9. Epub 2018 Nov 1. Lancet Oncol. 2018. PMID: 30392810
-
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Vaccine. 2008. PMID: 18847555 Review.
Cited by
-
Epidemiology and genotypes analysis of human papillomavirus infection in Huizhou, China.Front Public Health. 2024 Aug 9;12:1440480. doi: 10.3389/fpubh.2024.1440480. eCollection 2024. Front Public Health. 2024. PMID: 39185110 Free PMC article.
-
Combined incentive actions, focusing on primary care professionals, to improve cervical cancer screening in women living in socioeconomically disadvantaged geographical areas: a study protocol of a hybrid cluster randomised effectiveness and implementation trial- RESISTE.BMJ Open. 2022 Nov 23;12(11):e065952. doi: 10.1136/bmjopen-2022-065952. BMJ Open. 2022. PMID: 36418118 Free PMC article.
-
Women's knowledge, attitude, and practice regarding cervical precancerous lesions: a cross-sectional study in Beijing, China.Front Public Health. 2024 Oct 2;12:1433718. doi: 10.3389/fpubh.2024.1433718. eCollection 2024. Front Public Health. 2024. PMID: 39416937 Free PMC article.
-
Early salvage therapy with anti-PD-1 antibody Camrelizumab in patients with advanced cervical cancer: a retrospective study.Clin Transl Oncol. 2025 Feb;27(2):693-698. doi: 10.1007/s12094-024-03610-5. Epub 2024 Jul 20. Clin Transl Oncol. 2025. PMID: 39033255
-
A comparative analysis of toxicity and treatment outcomes of adaptive radiotherapy and intensity-modulated radiotherapy in cervical cancer.Sci Rep. 2025 Jan 10;15(1):1609. doi: 10.1038/s41598-024-85074-9. Sci Rep. 2025. PMID: 39794450 Free PMC article.
References
-
- zur Hausen H Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 1989;49:4677–81. - PubMed
-
-
A call to action to eliminate cervical cancer globally. Available online: https://www.uicc.org/news/a%C2%A0call-action-eliminate-cervical-cancer-globally
-
-
-
WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. Available online: https://www.paho.org/hq/index.php?option=com_content&view=article&id=14358:who-director-general-calls-for-all-countries-to-take-action-to-help-end-the-suffering-caused-by-cervical-cancer&Itemid=40591&lang=en
-
LinkOut - more resources
Full Text Sources